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ABSTRACT 
Objective: The reason behind the occurrence of Neural Tube Defects (NTDs) in pregnant women treated with certain Anti-Epileptic Drugs (AEDs) 
such as Carbamazepine, Valproate, Lamotrigine, Phenobarbital, etc., is not yet known. The relationship between Folic Acid intake and NTDs is not 
yet established. Folate receptors play a critical role in mediating placental transport of maternal folate to the foetus. Another important protein is 
Carnitine O-acetyltransferase that is involved in the transport of carnitine, which is much needed for foetal metabolic functions and tissue 
development. The objective of this study is to understand the interaction of AEDs with two important placental proteins through a docking 
approach to establishing a suitable explanation of AED’s role in NTD. 
Methods: A generic algorithm based docking was used to identify and study the mode of interactions between the drugs and placental proteins. For 
comparison purpose, the natural ligands of these receptors have also been included in the dataset containing AEDs. 
Results: Both bonded and non-bonded interactions were observed between AEDs and the crucial residues of these proteins. The drugs formed 
complex with these proteins with satisfactory binding energy. Some amount of Electrostatic interaction was also observed among a few pairs of 
protein residue and drug molecules.  
Conclusion: We suggest that these drug-protein associations, involving bonded and non-bonded interactions, could be a possible portal by which 
certain AEDs induce NTDs in the foetus. Higher interaction of Pantothenic Acid with Folate Receptor could be a mechanism through which 
Pantothenic Acid inhibits Valproic Acid-induced NTDs. And thus, its supplementation can specifically prevent Valproic Acid-induced NTDs. The 
above mechanism also explains how increased intake of Folic Acid during pregnancy can reduce the occurrence of NTDs.  
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INTRODUCTION 
Neural Tube is a precursor to the Brain and Spinal cord in an Embryo. 
The Neural tube begins being formed after 21 d (3 w) after fertilization 
by a process called Neurulation. Neural tube formation is complete by 
the 4th week after fertilization [1]. NTDs are common congenital 
malformations that occur when the embryonic neural tube fails to close 
properly during the first few weeks of development. The reported NTD 
incidence in India varies from 0.5 to 11/1000 birth [2]. NTDs may be 
broadly classified into Spina Bifida and Anencephaly. Spina Bifida refers 
to incomplete development and fusion of one or more vertebral arches 
with associated involvement of the posterior neural tube. Anencephaly 
results from failed closure of the anterior neural tube, with the absence 
of the bones of the cranial vault and absent or rudimentary cerebral and 
cerebellar hemispheres and brainstem [3]. 
Epilepsy is a brain disorder involving repeated, spontaneous 
seizures of any type. Seizures, or convulsions, are episodes of 
disturbed brain function that cause changes in attention or 
behaviour. They are caused by abnormally excited electrical signals 
in the brain. The vast majority of patients suffering from seizures 
requires daily AED therapy, and in most instances, this is a lifelong 
treatment. This also holds true for epileptic women falling within the 
reproductive age group [3]. 50 million people worldwide are 
affected with epilepsy and half of these are women. There are 
approximately 2.7 million women with epilepsy in India, and 52% of 
the women are in the reproductive age group (15-49 y) [4]. For the 
most part, the clinical course of pregnancies in women with epilepsy 
is uneventful, with most children born free from either structural or 
behavioural abnormalities. However, given the in utero exposure to 
AEDs, these children are at a greater risk of being born with birth 
defects [3]. Commonly used AEDs include Carbamazepine, 
Phenytoin, Lamotrigine, Levetiracetam, Phenobarbital, Topiramate, 
Valproate and Vigabatrin [3, 5]. 
Folic acid is the fully oxidized mono glutamyl form of water-soluble 
vitamin B9 that is used commercially in supplements and in fortified 
foods. Metabolically, folic acid is converted to coenzyme forms 
required in various one-carbon transfer reactions, including synthesis, 
conversion and modification of nucleotides, amino acids and other 
essential compounds. Folic acid supplements taken periconceptional 
have been definitively proven to reduce the risk of neural tube defects 
significantly. Human Folate Receptors (FRs) are high-affinity receptors 
that transport folate via endocytosis. They thus play a critical role in 
mediating placental transport of maternal folate to the foetus 
[6]. Limiting the availability of folic acid to cells within the embryo will 
compromise normal growth and development of the embryo [7]. 
Another important compound is L-carnitine, which is highly polar 
and plays an important role in transferring the long chain fatty acids 
across the inner mitochondrial membrane, the detoxification of toxic 
acyl moieties and the regulation of apoptosis and oxidative stress. 
Carnitine is important in the foetus for the maturation of carnitine 
reserve, metabolic functions and tissue development, especially the 
neural tube [8]. Carnitine O-acetyl transferase (CRAT) helps to 
transport carnitine from mother to foetus. 
So far, no study has concluded the way by which the AEDs cause NTD 
in the foetus. Placental proteins that can be specifically associated with 
NTDs have also not been stated as a fact. Through this study, we have 
attempted to find a mechanism that would probably be adopted by the 
AEDs to cause NTD and to hypothesize proteins involved in neural 
tube defects. Based on the extensive literature work, we have 
considered two important placental proteins Human Folate Receptors 
and Carnitine O-Acetyl transferase for our study. A small dataset 
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comprising of selected AEDs and natural ligands to the proteins were 
considered. Our paper further aims to explain a route by which 
Pantothenic Acid inhibits Valproic Acid-induced NTDs. The interaction 
between the proteins and the ligands has been quantified with a 
computational approach of docking.  
 Table 1: Accession numbers of protein data used in this study 
Protein name Uniprot ID PDB ID 
Folate Receptor [11] P14207 4KN1 
Carnitine O-Acetyl Transferase [12] P43155 1S5O 
 
Table 2: Information about ligand structures obtained from PubChem 
Compound name 2D Structure PubChem ID Molecular weight (g/mol) 
Folic Acid 
 
CID_6037 441.397460  
Pantothenic Acid 
 
CID_6613 219.234980  
Lamotrigine 
 















CID_5284627 339.362040  
Gabapentin 
 
CID_3446 171.236780  
Valproate 
 
CID_3121 144.211440  
Mildronate 
 
CID_123868 146.187560  
Vigabatrin 
 
CID_5665 129.157040  
Carnitine 
 
CID_85 162.206840  
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MATERIALS AND METHODS 
Works of literature were read to identify proteins that could be 
required for neural tube formation and closure. The dataset 
comprised Lamotrigine (LMT), Pantothenic Acid (PA), 
Carbamazepine (CBZ), Phenytoin (PHT), Phenobarbital (PB), 
Levetiracetam (LEV), Topiramate (TPM), Gabapentin (GBP), 
Valproate (Valproic Acid-VPA), Mildronate (MI) and Vigabatrin 
(VGB) along with natural substrates [Folic Acid (FA) and Carnitine 
(CA)] [3]. Protein information was obtained from Uniprot Database 
[9]. Protein structures were retrieved from the Protein Data Bank 
(PDB) [10] and Ligand structures from PubChem. 
The interactions between proteins and ligands were studied using 
iGEMDOCK, a Graphical Environment for Recognizing 
Pharmacological Interactions and Virtual Screening. It is easy-to-use 
software for docking, virtual screening, and post-screening analysis. 
The pharmacological interactions represent conserved interacting 
residues that often form binding pockets with specific 
physicochemical properties to play the essential functions of the 
target protein [13]. Molecular graphics and analyses were 
performed with the UCSF Chimera package. Chimera is developed by 
the Resource for Biocomputing, Visualization, and Informatics at the 
University of California, San Francisco [14]. 
RESULTS AND DISCUSSION 
As per the crystal structure, folic acid binds to amino acids such as 
R119, D97, Y101, W118, W187, W156, W154, H151, G153 and S190. 
It was observed that the folic acid prefers a binding pocket rich in 
hydrophobic amino acid, tryptophan, with which it exhibited both 
bonded and non-bonded interactions. The docking results reflected 
the favourable interactions between drugs and crucial residues of FR 
which are evident from the docking energies as tabulated below in 
table 3 and as shown in fig. 1. The interaction energy of the ligand with 
the protein is the sum of the Vander Waals Force, electrostatic energy 
and energy through Hydrogen bonds. In tables, Residues showed as 
italics exhibit electrostatic interaction with the amino acids while the 
residues represented as bold exhibit Vander Waals interaction. The 
other residues exhibit Hydrogen bonded interaction. More negative 
the total energy, better the interaction between the protein and 
Ligand/Drug. In this case, the van der Waals interaction contributed 
more to the binding energy than the other interactions. Most of the 
ligands interacted with the tryptophan residues present in the active 
site. Drugs like VPA, GBP, MI and VGB docked with the basic amino 
acid R119 through electrostatic attraction and hydrogen bond with its 
side chain. FA exhibited only Vander Waals interaction with the side 
chain of R119 and it did not show electrostatic interaction with any of 
the active site residues.  
  
Table 3: Energy of the interaction of drugs with Folate receptor and critical residues involved in the interactions 
Drug Name Total Energy Vander Waal HBond Elec Interacting Residues 
Folic Acid -175.5 -136.51 -38.67 -0.33 D97  W118  W154  W156  W187  S190 D97  
Y101  W118  H151  W156  W187 
Lamotrigine -108.9 -81.43 -27.47 0 D97 S190 D97  Y101 W118 H151 W156 W187 
Carbamazepine -107.2 -100.31 -6.928 0 D97  Y101  W118  H151 W187 
Phenytoin -101.1 -80.56 -20.54 0 D97  T98 D97  Y101  W118  H151  W156 W187 
Phenobarbital -98.3 -80.48 -17.81 0 D97  T98 D97  Y101  W118 W187 
Pantothenic acid -97.3 -64.02 -27.49 -5.74 R119 D97  W187 D97  Y101  W118  H151  W187 
Levetiracetum -92.1 -67.45 -24.64 0 D97  Y101  W187 D97  Y101  W187 
Topiramate -86.1 -68.03 -18.05 0 D97  W187  S190 D97 Y101 Q118 H151 W187 
Gabapentin -80.3 -56.47 -18.74 -5.06 R119 D97 Y101 W118  H151  W187 
Valproate -77.2 -57.60 -13.91 -5.67 R119 D97 Y101 W118 H151 W187 
Mildronate -73.4 -56.90 -10.35 -6.18 R119 D97  Y101  W118  H151  W187 
Vigabatrin -72.8 -49.61 -17.84 -5.32 R119 D97 D97  Y101 W118 W187 
 







HBond Elec Interacting Residues 
Topiramate -98.1 -68.04 -30.05 0 H322 T444 H322 Y431 S433 
Phenytoin -94.7 -75.17 -19.52 0 S433 
H322 Y431 S433 
Lamotrigine -88.5 -60.35 -28.17 0 H322 Y431 S433 
Carbamazepine -87.6 -75.64 -11.93 0 H322 S433 
H322 Y431 S433 
Pantothenic acid -85.5 -55.01 -28.88 -1.58 H322 
H322 
H322 Y431 S433 
Phenobarbital -80.2 -60.63 -19.56 0 H322 S433 
H322 Y431 S433 
Gabapentin -68.2 -48.32 -18.85 -1.01 H322 
H322 
H322 Y431 S433 
Carnitine -67.3 -46.28 -19.55 -1.51 H322 
H322 
H322 S433 
Levetiracetam -66.4 -53.78 -12.64 0 H322 
H322 Y431 S433 
Vigabatrin -63.2 -44.20 -18.18 -0.82 H322 
H322 
H322 S433 
Mildronate -62.8 -46.76 -14.36 -1.62 H322 
H322 
H322 S433 
Valproate -61.4 -45.11 -15.00 -1.31 H322 
H322 
H322 Y431 S433 
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It was noted that the vitamin PA, which has been proved to decrease 
the VPA-induced neural tube defects, showed interactions similar to 
VPA, but the binding energy was higher for PA [5]. This could be a 
factor of FR’s preference to PA over VPA. Another noted 
interaction of PA was hydrogen bond and van der Waals 
interactions with the side chain of acidic amino acid D97 which 
were not exhibited by VPA. Docking results showed that PA bound 
with crucial residues more strongly than the AEDs which are 
evident from the overall energy as well as the contribution from 
each interaction. This could possibly be a valid reason for the PA to 
be preferred by the receptor than the other. The interactions 
shown by AEDs to the active site residues show that the AEDs 
especially VPA could possibly act as antagonists to FR. 
The crystal structure of CRAT reveals that carnitine binds to a 
pocket that includes amino acids H322, T454, Y431, S433, E326, 
W81, V548, T532 and F545. Table4 describes the results of 
interactions between the drugs and CRAT. Few important drug-
receptor interactions are revealed in fig. 2. Docking results showed 
that TP, PH, LMT, CBZ, PHB and GBP bound with carnitine receptor 






Fig. 1: Bonded interactions of Folic acid, Pantothenic acid and 




Fig. 2: Bonded interactions of Carnitine, Pantothenic acid and 
Valproate with Carnitine O-Acetyltransferase. H-bonds are 
shown as red lines 
 
Most of total energy derives from the van der Waals interactions of 
drugs with the protein. Docking results showed that VPA, GBP, MI and 
VGP showed an electrostatic attraction to H322, which is one of the 
crucial residues. Natural ligand, carnitine also showed an electrostatic 
attraction to H322. The highest Electrostatic Static energy with the 
overall protein was shown by the PA and Carnitine. PA binds to many 
amino acids such as Y431, S433, S531, T532 and S533 to which VPA 
fails to bind. PA’s interaction with CRAT is stronger than VPA and 
carnitine as evident from the interactions and binding energy. These 
reasons could explain why PA is preferred over VPA, by CRAT. 
As shown by the dock scores, the hypothesis implying a preference 
of the protein to bind via bonded and non-bonded interactions give a 
possible explanation to the antagonistic/competitive binding of 
drugs to the protein. No substantial proof is available to associate 
specific proteins to Neural Tube Defects. Based on the results, we 
hypothesize FR and CRAT as potential targets that could play a 
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prominent role in the Neural tube formation and their inhibition by 
AEDs is associated with the occurrence of NTDs. 
CONCLUSION 
Our study shows that Neural Tube Defect causing Anti-Epileptic 
drugs shared potential interactions with two important placental 
proteins, Folate receptor and Carnitine O-Acetyltransferase. The 
binding of the Anti-Epileptic drugs with these crucial proteins makes 
them inefficient in their routine function thus resulting in Neural 
Tube Defect. This work suggests that these two placental proteins 
could play a significant role in Neural Tube formation. Both 
Valproate and Pantothenic acid compete for the active site of these 
two proteins as validated by docking. Based on the computational 
method, it is concluded that the Pantothenic acid binds to these 
receptors strongly than the Anti-Epileptic drugs suggesting the 
preference of it over other drugs. This competitive mechanism 
adopted by Pantothenic acid in binding to these proteins could be a 
strong rationale of reduction in valproate-induced Neural Tube Defect 
risks in patients under compulsory valproate treatment. This rationale 
derived from the computational method is much in understanding 
with the experiments done with Folic acid and carnitine [15, 16]. Thus, 
studying the effects of various drugs on these placental proteins can 
help to prevent their teratogenicity by reducing their risks of inducing 
Neural Tube defects. This work is the first of its kind to explain this fact 
through computational method. 
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